In a striking advancement in cardiovascular research, a groundbreaking study published in Nature Communications in 2026 unveils how the YY1/Asprosin/PFKP axis plays a pivotal role in modulating glycolytic metabolism and exacerbating pathological cardiac hypertrophy. This discovery sheds new light on the molecular mechanisms that drive cardiac remodeling under stress and opens new avenues for therapeutic intervention in heart disease.
The heart’s ability to adapt metabolically in response to physiological and pathological stimuli has long been a subject of intense scientific scrutiny. Heart cells are highly dependent on an intricate balance of energy production pathways to maintain proper function. Among these, glycolysis—the process by which glucose is broken down to produce energy—is crucial, especially under stress conditions. Disruptions in glycolytic flux are often associated with detrimental cardiac remodeling, such as hypertrophy, a condition characterized by enlarged cardiac muscle cells that can progress to heart failure.
At the core of this study lies Yin Yang 1 (YY1), a multifunctional transcription factor known to regulate a wide array of cellular processes, including proliferation, differentiation, and metabolism. YY1’s involvement in cardiac physiology, however, has remained poorly understood until now. The researchers elucidate how YY1 orchestrates an intricate signaling pathway involving Asprosin, a fasting-induced protein hormone, and phosphofructokinase platelet type (PFKP), a rate-limiting enzyme in glycolysis, to modulate energy metabolism in hypertrophic cardiomyocytes.
Asprosin, initially characterized as a glucogenic hormone secreted by white adipose tissue, has emerged as a critical metabolic regulator. This study reveals its novel paracrine role within cardiac tissue, mediating crosstalk between metabolic signaling and gene expression via YY1. By binding to YY1, Asprosin significantly influences the transcriptional activation of glycolytic genes, amplifying PFKP expression and accelerating glycolytic flux.
PFKP acts as a major control point within the glycolytic pathway, catalyzing the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate. Its activity effectively determines the pace of glycolysis, impacting ATP production and biosynthetic precursor availability. The overactivation of PFKP through the YY1/Asprosin signaling axis thus promotes heightened metabolic activity within cardiomyocytes, which becomes maladaptive during chronic stress, triggering pathological hypertrophy.
By employing a comprehensive suite of molecular techniques, including chromatin immunoprecipitation sequencing (ChIP-seq), metabolomic profiling, and advanced cardiac imaging, the research team meticulously mapped the regulatory network underpinning this axis. Their findings demonstrate that YY1 directly binds to the promoter region of the PFKP gene, facilitating transcriptional upregulation in response to Asprosin signaling. This transcriptional cascade intensifies glycolytic metabolism, causing an energetic imbalance that propels cardiomyocyte enlargement and maladaptive remodeling.
Intriguingly, mouse models genetically modified to overexpress Asprosin in cardiac tissue developed pronounced hypertrophic phenotypes characterized by increased heart size, fibrosis, and reduced cardiac output. Conversely, silencing either YY1 or PFKP in these models effectively mitigated hypertrophy, underscoring the therapeutic potential of targeting components within this axis.
The study also delves into the signaling intermediates modulated by YY1 and Asprosin, including AMP-activated protein kinase (AMPK) and hypoxia-inducible factor 1-alpha (HIF-1α). It appears that YY1 activation enhances glycolytic flux partly through cross-regulation of these metabolic sensors, establishing a feedback loop that exacerbates metabolic dysfunction during pathological stress.
This metabolic dysregulation correlates with an increase in reactive oxygen species (ROS) production and mitochondrial dysfunction, further compounding cellular stress and contributing to the progression of cardiac hypertrophy. Through sophisticated electron microscopy and mitochondrial respiration assays, the authors revealed that mitochondrial integrity is compromised when the YY1/Asprosin/PFKP axis is hyperactivated.
Beyond its implications for cardiac hypertrophy, this research expands the understanding of Asprosin’s systemic roles, implicating it as a key mediator in metabolic diseases linked to cardiovascular complications. Elevated circulating Asprosin levels have previously been reported in obesity and type 2 diabetes; thus, its involvement in heart disease may represent a unifying mechanism driven by metabolic derangements.
The translational significance of these findings is profound. By dissecting the molecular players involved in the YY1/Asprosin/PFKP axis, this work paves the way for innovative therapeutic strategies aimed at modulating glycolytic metabolism within the heart. Pharmacological inhibitors targeting PFKP or blocking Asprosin interactions could potentially arrest or reverse maladaptive cardiac hypertrophy, offering hope for millions affected by heart failure worldwide.
Furthermore, this study exemplifies the power of integrative multi-omics approaches coupled with precise in vivo modeling to unravel complex biological networks. The identification of YY1 as a master transcriptional regulator within the metabolic landscape of the heart underscores the intricate dependency of transcriptional control and cellular bioenergetics in disease pathology.
Future investigations will be needed to explore how this axis interacts with other metabolic regulators, such as fatty acid oxidation and mitochondrial biogenesis pathways. Understanding the broader metabolic rewiring associated with YY1/Asprosin/PFKP axis modulation could reveal additional therapeutic targets and biomarkers for early detection of pathological hypertrophic remodeling.
In conclusion, the discovery of the YY1/Asprosin/PFKP axis as a critical modulator of glycolytic metabolism that exacerbates pathological cardiac hypertrophy represents a paradigm shift in cardiovascular biology. This sophisticated regulatory circuit not only links metabolic signaling and gene expression but also provides a timely target for combating one of the leading causes of morbidity and mortality worldwide—the progression of cardiac hypertrophy to heart failure. The study charts a new course for metabolic therapeutics tailored to the complexities of cardiac disease, exemplifying the fusion of molecular discovery and clinical applicability.
Subject of Research: Cardiac metabolism and pathological hypertrophy mechanisms.
Article Title: YY1/Asprosin/PFKP axis regulates glycolytic metabolic and exacerbates pathological cardiac hypertrophy.
Article References:
Tong, M., Liu, X., Yu, Y. et al. YY1/Asprosin/PFKP axis regulates glycolytic metabolic and exacerbates pathological cardiac hypertrophy.
Nat Commun (2026). https://doi.org/10.1038/s41467-026-71197-2
Image Credits: AI Generated
Tags: Asprosin hormone role in heart diseaseenergy metabolism in cardiomyocytesfasting-induced hormones and heart functionglycolysis disruption in heart failuremetabolic adaptation in cardiac stressmodulation of glycolytic flux in heart diseasemolecular mechanisms of cardiac remodelingPFKP enzyme in glycolytic metabolismsignaling pathways in pathological hypertrophytherapeutic targets for cardiac hypertrophyYY1 transcription factor in cardiac hypertrophyYY1/Asprosin/PFKP axis in cardiovascular research
